Grifols Therapeutics Llc
Clinical trials sponsored by Grifols Therapeutics Llc, explained in plain language.
US subsidiary of Grifols, a global plasma-derived medicines company.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Could a simple shot replace IV drips for Alpha-1 patients?
Disease control Recruiting nowThis study tests a new way to give Alpha1-Proteinase Inhibitor—a medicine that helps protect the lungs in people with Alpha-1 Antitrypsin Deficiency. Instead of getting it through a vein at a clinic, participants will receive it as a weekly injection under the skin. The trial wil…
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for blood cancer patients: drug aims to slash infection risk
Disease control Recruiting nowThis study tests whether a medicine called XEMBIFY, given every two weeks alongside standard care, can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who also have low antibody lev…
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New weekly shot could replace IV drips for nerve disease
Disease control Recruiting nowThis study tests whether a weekly under-the-skin antibody treatment (XEMBIFY) provides similar blood levels as a standard IV infusion (Gamunex-C) given every 3 weeks in people with CIDP, a chronic nerve disorder. About 40 adults who are stable on IVIG will first receive Gamunex-C…
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC